---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-21-007693"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2021-07-07T23:59:59+00:00"
generated_at: "2026-06-30T07:03:33.877686+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI Reports 14.1% 5-Year Survival Benefit in Phase 3 Multikine Trial; Plans FDA Submission

## Summary
- Multikine showed a statistically significant 14.1% absolute improvement in 5-year overall survival in patients receiving surgery plus radiotherapy (n=380).
- The successful treatment arm represents 40% of the study population, estimated at 155,000 newly diagnosed advanced head and neck cancer patients annually.
- Analysis of the surgery plus radiation arm was pre-specified in the protocol and statistical analysis plan before unblinding, permitting FDA submission use.
- Company intends to meet with FDA for pre-BLA meeting and file for approval of Multikine in this patient population.
- No safety issues were identified; the survival benefit increased over time with a hazard ratio of 0.68 (p=0.0236).

## SEC filing metadata
- accession: 0001654954-21-007693
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2021-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495421007693/0001654954-21-007693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495421007693/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-21-007693
- JSON: https://secwatch.observer/filing/0001654954-21-007693.json
- Plain text: https://secwatch.observer/filing/0001654954-21-007693.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.